Targeting Nitric Oxide: Say NO to Metastasis

Tejaswini P. Reddy, Sharon A. Glynn, Timothy R. Billiar, David A. Wink, Jenny C. Chang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Utilizing targeted therapies capable of reducing cancer metastasis, targeting chemoresistant and self-renewing cancer stem cells, and augmenting the efficacy of systemic chemo/ radiotherapies is vital to minimize cancer-associated mortality. Targeting nitric oxide synthase (NOS), a protein within the tumor microenvironment, has gained interest as a promising therapeutic strategy to reduce metastatic capacity and augment the efficacy of chemo/radiotherapies in various solid malignancies. Our review highlights the influence of nitric oxide (NO) in tumor progression and cancer metastasis, as well as promising preclinical studies that evaluated NOS inhibitors as anticancer therapies. Lastly, we highlight the prospects and outstanding challenges of using NOS inhibitors in the clinical setting.

Original languageEnglish
Pages (from-to)1855-1868
Number of pages14
JournalClinical Cancer Research
Issue number10
StatePublished - 15 May 2023
Externally publishedYes


Dive into the research topics of 'Targeting Nitric Oxide: Say NO to Metastasis'. Together they form a unique fingerprint.

Cite this